Zimmer Biomet/$ZBH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zimmer Biomet
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
- Ticker
- $ZBH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 17,000
- Headquarters
- Warsaw, United States
- Website
- www.zimmerbiomet.com
Zimmer Biomet Metrics
BasicAdvanced
$17B
22.25
$4.12
0.47
$0.96
1.05%
Price and volume
Market cap
$17B
Beta
0.47
52-week high
$106.88
52-week low
$79.12
Average daily volume
1.9M
Dividend rate
$0.96
Financial strength
Current ratio
1.691
Quick ratio
0.741
Long term debt to equity
0.497
Total debt to equity
0.602
Dividend payout ratio (TTM)
23.35%
Interest coverage (TTM)
4.90%
Profitability
EBITDA (TTM)
2,520.9
Gross margin (TTM)
69.52%
Net profit margin (TTM)
9.48%
Operating margin (TTM)
16.60%
Effective tax rate (TTM)
13.56%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
3.87%
Return on equity (TTM)
6.41%
Valuation
Price to earnings (TTM)
22.246
Price to revenue (TTM)
2.105
Price to book
1.38
Price to tangible book (TTM)
-9.93
Price to free cash flow (TTM)
16.601
Free cash flow yield (TTM)
6.02%
Free cash flow per share (TTM)
5.516
Dividend yield (TTM)
1.05%
Forward dividend yield
1.05%
Growth
Revenue change (TTM)
8.62%
Earnings per share change (TTM)
0.17%
3-year revenue growth (CAGR)
5.75%
10-year revenue growth (CAGR)
1.22%
3-year earnings per share growth (CAGR)
19.72%
10-year earnings per share growth (CAGR)
14.15%
10-year dividend per share growth (CAGR)
0.43%
What the Analysts think about Zimmer Biomet
Analyst ratings (Buy, Hold, Sell) for Zimmer Biomet stock.
Analyst projections of the future price of Zimmer Biomet stock.
Bulls say / Bears say
Second-quarter organic constant-currency sales grew 4%, and Zimmer Biomet raised its full-year organic growth outlook to 2.25%–3.25%. This suggests recent trading is improving beyond its earlier cautious forecast. (Zimmer Biomet)
Technology, data, bone cement and surgical sales rose 21.5% in the second quarter, with record capital sales for ROSA and TMINI and early sales from the upgraded ROSA Shoulder. Faster adoption of surgical robotics could add a growth stream beyond implants. (Zimmer Biomet, MassDevice)
The hip franchise grew 5.1% in the second quarter, while adoption of the Z1 stem and OrthoGrid navigation has been building. This product combination may help Zimmer Biomet win more procedures and sustain hip growth. (ORTHOWORLD, MarketBeat)
The shift to a more specialised U.S. sales force has disrupted customer relationships, including the loss of two large accounts, and management still flags disruption risk from its commercial changes. If the transition takes longer than planned, it could restrain sales. (Reuters, The Motley Fool)
Profitability is under pressure: adjusted gross margin fell 120 basis points and operating margin fell 210 basis points year on year in the second quarter. Pricing erosion and higher manufacturing costs could limit how much sales growth reaches earnings. (The Motley Fool)
Growth across the portfolio is uneven: knee sales were almost flat in the second quarter, while management cited continued pressure in trauma and restorative therapies. Weakness in these product lines could offset momentum in hips and robotics. (MarketBeat, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Zimmer Biomet Financial Performance
Revenues and expenses
Zimmer Biomet Earnings Performance
Company profitability
Upcoming events
Zimmer Biomet News
AllArticlesVideos
Funds containing Zimmer Biomet
AllEURGBPUSD
Fund name | Fund size | $ZBH weighting |
|---|---|---|
VanEck Morningstar Wide Moat€GMVM | €407M | 2.48% |
VanEck Morningstar Wide Moat£MOGB | £354M | 2.48% |
iShares Ageing Population€AGED | €822M | 0.49% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.28% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.